We would like to point out an error appearing in the article on topical cidofovir by Toro et al.1 In the "Solution" section, the first sentence reads, "Topical 3% cidofovir was compounded as follows: 15 g of cidofovir (75 mg/mL) was mixed with 22.5 g of a combination vehicle (Dermovan; Galderma Laboratory Inc, Fort Worth, Tex)."
Cidofovir (Vistide Injection; Gilead Sciences, Inc, Foster City, Calif) is supplied at a concentration of 75 mg/mL and packaged as 375 mg in a 5-mL single-unit glass vial. To add 15 g of cidofovir to the vehicle would require adding 200 mL of cidofovir solution. The resulting mixture would have a final concentration of 6.7%.
Goldblum OM, Zabawski EJ. Compounding of Topical Cidofovir. Arch Dermatol. 2002;138(2):267. doi:10.1001/archderm.138.2.266
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: